U.S. Pharmaceuticals Industry Analysis and Trends 2023
U.S. (United States) pharmaceutical market is the largest pharmaceuticals market in the world and accounted for more than 40% global pharmaceuticals sales in 2017. USA pharmaceuticals market is expected to grow in the upcoming years despite recent slowdown due to price erosion in U.S. generics pharmaceuticals market, delay in approval of complex generics by US FDA (United States Food and Drug Administration) and Government’s talks of drug price control mechanism like other major pharmaceutical markets. The reasons are simple: aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases.
As per NAVADHI Market Research, the U.S. pharmaceutical industry will we worth USD 685.45 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
U.S. is expected to retain it’s leading position in the global pharmaceuticals market with market share of 43.72% in 2023 improving on it’s market share compared to 2017.
This growth is fuelled by the growing and ageing population in U.S. More than 15% of U.S. population is above 65 years of age and this number is expected to rise by 2023. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of U.S. pharma industry. The income level of average American is expected to rise by 3.21% CAGR by 2023, due to rising employment levels and stable economic conditions. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and speciality diseases. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry by even non-pharma companies like Facebook, Qualcomm etc. which is also driving the U.S. pharmaceuticals industry growth.
On the other hand, United States government’s plan to implement of cost control policies along with tightening of rules by government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market are expected to impact the growth prospect of the U.S. pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the U.S. pharma market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug.
Navadhi has provided detailed company profiles including their position in U.S pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for top 10 companies in U.S. pharmaceuticals market by their pharmaceuticals revenue namely: Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Amgen, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., Sanofi S.A and Bristol-Myers Squib
Scope of the U.S. Pharmaceuticals Industry Analysis and Trends 2023 Report
As per NAVADHI Market Research, the U.S. pharmaceutical industry will we worth USD 685.45 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.
U.S. is expected to retain it’s leading position in the global pharmaceuticals market with market share of 43.72% in 2023 improving on it’s market share compared to 2017.
This growth is fuelled by the growing and ageing population in U.S. More than 15% of U.S. population is above 65 years of age and this number is expected to rise by 2023. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of U.S. pharma industry. The income level of average American is expected to rise by 3.21% CAGR by 2023, due to rising employment levels and stable economic conditions. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and speciality diseases. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry by even non-pharma companies like Facebook, Qualcomm etc. which is also driving the U.S. pharmaceuticals industry growth.
On the other hand, United States government’s plan to implement of cost control policies along with tightening of rules by government like delay in approval of complex generics and price erosion in U.S. generics pharmaceuticals market are expected to impact the growth prospect of the U.S. pharmaceuticals industry. Pharmaceuticals companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the U.S. pharma market as new drugs revenue form large part of pharma firm’s revenue due to exclusivity of the drug.
Navadhi has provided detailed company profiles including their position in U.S pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for top 10 companies in U.S. pharmaceuticals market by their pharmaceuticals revenue namely: Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Amgen, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., Sanofi S.A and Bristol-Myers Squib
Scope of the U.S. Pharmaceuticals Industry Analysis and Trends 2023 Report
- This report provides detailed information about United States pharmaceuticals market including future market forecasts up to 2023.
- This report identifies the need for focusing on U.S. pharmaceuticals market
- The report identifies the growth drivers and inhibitors for U.S. pharmaceuticals market.
- The report identifies various risks associated with U.S. pharmaceuticals market.
- This report has detailed profiles of top 10 companies in U.S. pharmaceuticals market by their pharmaceutical revenue covering their position in pharmaceuticals value chain, business strategy, financial performance, future forecasts and SWOT analysis.
- This report provides competitive landscape among top 10 pharmaceutical companies in U.S. market.
- This report provides Porter’s Five Forces analysis for U.S. pharmaceuticals market.
- This report provides SWOT (strengths, weakness, opportunities and threats) analysis for U.S. pharmaceuticals market.
- This report provides information about current and future trends for U.S. pharmaceuticals market.
1. EXECUTIVE SUMMARY
Scope of the U.S. Pharmaceuticals Industry Analysis and Trends 2023 Report
Research Methodology
2. INTRODUCTION OF U.S. PHARMACEUTICALS MARKET
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
U.S. Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR U.S. PHARMACEUTICALS MARKET
Rising & Ageing U.S. Population
Increasing Income Levels of Poor & Middle-Class Families
4. FORECAST FOR U.S. PHARMACEUTICALS MARKET 2023
4.1 Forecast for North America Pharmaceuticals Market 2018-2023
4.1.1 Forecast for U.S. Pharmaceuticals Market 2018-2023
5. GROWTH DRIVERS AND INHIBITORS FOR U.S. PHARMACEUTICALS MARKET
6. RISKS ASSOCIATED WITH U.S. PHARMACEUTICALS MARKET
6.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
6.2 Risk of Commercial Success of New Products
6.3 Risk of Failed Research and Development Effort
6.4 Risk of Drug Price Controls
6.5 Risk of Failure to Comply with New Laws and Regulations
6.6 Risk of Quality Control During Complex Manufacturing Process
6.7 Risk of Cyber-Attacks and Data Breach
6.8 Risk of Volatile Currency Exchange Rates and Interest Rates
6.9 Risk of Unstable Global Political and Economic Conditions
7. GOVERNMENT BODIES AND INDUSTRY ASSOCIATIONS RELATED TO U.S. PHARMACEUTICALS MARKET
7.1 Food and Drug Administration (FDA)
7.2 American Association of Pharmaceutical Scientists (AAPS)
7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)
7.4 Association for Accessible Medicines (AAM)
8. PROFILE OF TOP 10 COMPANIES IN U.S. PHARMACEUTICALS MARKET
8.1 Pfizer Inc.
8.1.1 Company Profile
8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.1.3 Pfizer Inc.: Financial Performance
8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.1.4 Pfizer Inc.: Business Strategy
8.1.4.1 Product Level Strategy
8.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
8.2 Johnson & Johnson
8.2.1 Company Profile
8.2.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
8.2.3 Johnson & Johnson Financial Performance
8.2.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.2.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
8.2.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
8.2.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.2.4 Johnson & Johnson: Business Strategy
8.2.4.1 Product Level Business Strategy
8.2.5 Johnson & Johnson’s Pharmaceutical Division Growth Drivers
8.2.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
8.3 Roche Holding AG
8.3.1 Company Profile
8.3.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
8.3.3 Roche Holding AG: Financial Performance
8.3.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
8.3.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
8.3.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
8.3.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
8.3.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
8.3.4 Roche Holding AG: Business Strategy
8.3.4.1 Product Level Strategy
8.3.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
8.3.6 Key Customers of Roche Holding AG
8.4 AbbVie Inc.
8.4.1 Company Profile
8.4.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.4.3 AbbVie Inc.: Financial Performance
8.4.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.4.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.4.4 AbbVie Inc.: Business Strategy
8.4.4.1 Product Level Strategy
8.4.5 SWOT Analysis of AbbVie Inc.
Strengths
Weaknesses
Opportunities
Threats
8.5 Amgen Inc.
8.5.1 Company Profile
8.5.2 Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.5.3 Amgen Inc. and Company: Financial Performance
8.5.3.1 Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.5.3.2 Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.5.3.3 Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.5.3.4 Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.5.3.5 Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.5.4 Amgen Inc.: Business Strategy
8.5.4.1 Product Level Strategy
8.5.5 SWOT Analysis of Amgen Inc.
Strengths
Weaknesses
Opportunities
Threats
8.6 Novartis AG
8.6.1 Company Profile
8.6.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
8.6.3 Novartis AG: Financial Performance
8.6.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.6.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
8.6.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.6.4 Novartis AG: Business Strategy
8.6.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
8.7 Merck & Co., Inc.
8.7.1 Company Profile
8.7.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.7.3 Merck & Co., Inc.: Financial Performance
8.7.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.7.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.7.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.7.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.7.4 Merck & Co., Inc.: Business Strategy
8.7.4.1 Product Level Strategy
8.7.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
8.8 Gilead Sciences Inc.
8.8.1. Company Profile
8.8.2 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.8.3 Gilead Sciences, Inc.: Financial Performance
8.8.4 Gilead Sciences, Inc.: Geography wise Performance
8.8.5 Gilead Sciences, Inc.: Business Strategy
8.8.6 SWOT Analysis of Gilead Sciences, Inc.
Strengths
Weaknesses
Opportunities
Threats
8.9 Sanofi S.A.
8.9.1 Company Profile
8.9.2 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
8.9.3 Sanofi S.A.: Financial Performance
8.9.3.1 Sanofi S.A.: Geography-Wise Revenue
8.9.4 Sanofi S.A.: Business Strategy
8.9.4.1 Sanofi S.A. Revenue by Global Business Units (GBU’s)
8.9.4.2 Sanofi S.A. Revenue by Global Franchise
8.9.5 SWOT Analysis of Sanofi S.A.
Strengths
Weaknesses
Opportunities
Threats
8.9.6 Sanofi’s TOP 10 Blockbusters Drugs Revenue in FY 2018 (in Euro millions)
8.10 Bristol-Myers Squibb Company
8.10.1 Company Profile
8.10.2 Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
8.10.3 Bristol-Myers Squibb Company: Financial Performance
8.10.3.1 Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.10.3.2 Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
8.10.3.3 Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.10.4 Bristol-Myers Squibb Company: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bristol-Myers Squibb Company
Strengths
Weaknesses
Opportunities
Threats
9. COMPETITIVE LANDSCAPE IN U.S. PHARMACEUTICALS MARKET
9.1 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue
9.2 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Global Pharmaceuticals Revenue
9.3 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by United States Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Development (R&D) Expenditure
9.5 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earning Per Share (EPS)
9.6 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.7 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue Forecast
9.8 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Top 3 Product Revenues
10. ANALYSIS OF U.S. PHARMACEUTICALS MARKET
10.1 Porter’s Five Forces Analysis of U.S. Pharmaceuticals Market
10.2 SWOT Analysis of U.S. Pharmaceuticals Market
Strengths
Weaknesses
Opportunities
Threats
11. CURRENT AND FUTURE TRENDS IN U.S. PHARMACEUTICALS MARKET
Orphan Drugs
Biologics and Biosimilars
CURRENT TRENDS
1. Increasing Severity of Drug Price Controls
2. Greater Focus on Rare Diseases / Orphan Drugs
3. Increasing Development of Nucleic Acids as Therapeutics
4. Increasing Focus on Cell Therapy
5. Implantables (Bioelectronics) and Electroceuticals are Expected to Become Mainstream
6. Use of 3D Printing to Reduce Cost and Improve Production Efficiency of Biologics
7. Increasing Use of Big Data and Artificial Intelligence (AI) in Drug Discovery
NOTES
COMPANY INFORMATION
Pfizer Inc.
Johnson & Johnson
Roche Holding AG
AbbVie Inc.
Amgen
Novartis AG
Merck & Co., Inc.
Gilead Sciences, Inc.
Sanofi S.A
Bristol-Myers Squib
Scope of the U.S. Pharmaceuticals Industry Analysis and Trends 2023 Report
Research Methodology
2. INTRODUCTION OF U.S. PHARMACEUTICALS MARKET
Key Product Terms Used in Pharmaceuticals Industry
Pharmaceuticals
Innovative Drugs
Orphan Drugs
Generic Drugs
Commodity Generic Drugs
Branded Generic Drugs
Biologics
Biosimilars
Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients (APIs)
Excipients
Research and Development (R&D) Phases of Pharmaceuticals Industry
Industry-Wise Research and Development (R&D) Investment
Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
U.S. Pharmaceuticals Industry Value Chain Analysis
3. NEED FOR U.S. PHARMACEUTICALS MARKET
Rising & Ageing U.S. Population
Increasing Income Levels of Poor & Middle-Class Families
4. FORECAST FOR U.S. PHARMACEUTICALS MARKET 2023
4.1 Forecast for North America Pharmaceuticals Market 2018-2023
4.1.1 Forecast for U.S. Pharmaceuticals Market 2018-2023
5. GROWTH DRIVERS AND INHIBITORS FOR U.S. PHARMACEUTICALS MARKET
6. RISKS ASSOCIATED WITH U.S. PHARMACEUTICALS MARKET
6.1 Risk of Patent Expiry and Loss of Intellectual Property Protection
6.2 Risk of Commercial Success of New Products
6.3 Risk of Failed Research and Development Effort
6.4 Risk of Drug Price Controls
6.5 Risk of Failure to Comply with New Laws and Regulations
6.6 Risk of Quality Control During Complex Manufacturing Process
6.7 Risk of Cyber-Attacks and Data Breach
6.8 Risk of Volatile Currency Exchange Rates and Interest Rates
6.9 Risk of Unstable Global Political and Economic Conditions
7. GOVERNMENT BODIES AND INDUSTRY ASSOCIATIONS RELATED TO U.S. PHARMACEUTICALS MARKET
7.1 Food and Drug Administration (FDA)
7.2 American Association of Pharmaceutical Scientists (AAPS)
7.3 Pharmaceutical Research and Manufacturers of America (PhRMA)
7.4 Association for Accessible Medicines (AAM)
8. PROFILE OF TOP 10 COMPANIES IN U.S. PHARMACEUTICALS MARKET
8.1 Pfizer Inc.
8.1.1 Company Profile
8.1.2 Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.1.3 Pfizer Inc.: Financial Performance
8.1.3.1 Pfizer Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.1.3.2 Pfizer Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.1.3.3 Pfizer Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.1.4 Pfizer Inc.: Business Strategy
8.1.4.1 Product Level Strategy
8.1.5 SWOT Analysis of Pfizer Inc.
Strengths
Weaknesses
Opportunities
Threats
8.2 Johnson & Johnson
8.2.1 Company Profile
8.2.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
8.2.3 Johnson & Johnson Financial Performance
8.2.3.1 Johnson & Johnson: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.2.3.2 Johnson & Johnson: Division-Wise Revenue FY 2018 (in USD billion)
8.2.3.3 Johnson & Johnson: Geography-Wise Revenue FY 2018 (in USD billion)
8.2.3.4 Johnson & Johnson: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.2.4 Johnson & Johnson: Business Strategy
8.2.4.1 Product Level Business Strategy
8.2.5 Johnson & Johnson’s Pharmaceutical Division Growth Drivers
8.2.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
8.3 Roche Holding AG
8.3.1 Company Profile
8.3.2 Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
8.3.3 Roche Holding AG: Financial Performance
8.3.3.1 Roche Holding AG: Overall Revenue FY 2013-FY 2019 (in CHF billion)
8.3.3.2 Roche Holding AG: Geography-Wise Revenue FY 2018 (in CHF billion)
8.3.3.3 Roche Holding AG: Division-Wise Revenue FY 2018 (in CHF billion)
8.3.3.4 Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018 (in CHF billion)
8.3.3.5 Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018 (in CHF billion)
8.3.4 Roche Holding AG: Business Strategy
8.3.4.1 Product Level Strategy
8.3.5 SWOT Analysis of Roche Holding AG
Strengths
Weaknesses
Opportunities
Threats
8.3.6 Key Customers of Roche Holding AG
8.4 AbbVie Inc.
8.4.1 Company Profile
8.4.2 AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.4.3 AbbVie Inc.: Financial Performance
8.4.3.1 AbbVie Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.4.3.2 AbbVie Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.4.3.3 AbbVie Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.4.4 AbbVie Inc.: Business Strategy
8.4.4.1 Product Level Strategy
8.4.5 SWOT Analysis of AbbVie Inc.
Strengths
Weaknesses
Opportunities
Threats
8.5 Amgen Inc.
8.5.1 Company Profile
8.5.2 Amgen Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.5.3 Amgen Inc. and Company: Financial Performance
8.5.3.1 Amgen Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.5.3.2 Amgen Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.5.3.3 Amgen Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.5.3.4 Amgen Inc.: Geography-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.5.3.5 Amgen Inc.: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.5.4 Amgen Inc.: Business Strategy
8.5.4.1 Product Level Strategy
8.5.5 SWOT Analysis of Amgen Inc.
Strengths
Weaknesses
Opportunities
Threats
8.6 Novartis AG
8.6.1 Company Profile
8.6.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
8.6.3 Novartis AG: Financial Performance
8.6.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.6.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)
8.6.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.6.4 Novartis AG: Business Strategy
8.6.5 SWOT Analysis of Novartis AG
Strengths
Weaknesses
Opportunities
Threats
8.7 Merck & Co., Inc.
8.7.1 Company Profile
8.7.2 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.7.3 Merck & Co., Inc.: Financial Performance
8.7.3.1 Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.7.3.2 Merck & Co., Inc.: Division-Wise Revenue FY 2018 (in USD billion)
8.7.3.3 Merck & Co., Inc.: Geography-Wise Revenue FY 2018 (in USD billion)
8.7.3.4 Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018 (in USD billion)
8.7.4 Merck & Co., Inc.: Business Strategy
8.7.4.1 Product Level Strategy
8.7.5 SWOT Analysis of Merck & Co., Inc.
Strengths
Weaknesses
Opportunities
Threats
8.8 Gilead Sciences Inc.
8.8.1. Company Profile
8.8.2 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
8.8.3 Gilead Sciences, Inc.: Financial Performance
8.8.4 Gilead Sciences, Inc.: Geography wise Performance
8.8.5 Gilead Sciences, Inc.: Business Strategy
8.8.6 SWOT Analysis of Gilead Sciences, Inc.
Strengths
Weaknesses
Opportunities
Threats
8.9 Sanofi S.A.
8.9.1 Company Profile
8.9.2 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
8.9.3 Sanofi S.A.: Financial Performance
8.9.3.1 Sanofi S.A.: Geography-Wise Revenue
8.9.4 Sanofi S.A.: Business Strategy
8.9.4.1 Sanofi S.A. Revenue by Global Business Units (GBU’s)
8.9.4.2 Sanofi S.A. Revenue by Global Franchise
8.9.5 SWOT Analysis of Sanofi S.A.
Strengths
Weaknesses
Opportunities
Threats
8.9.6 Sanofi’s TOP 10 Blockbusters Drugs Revenue in FY 2018 (in Euro millions)
8.10 Bristol-Myers Squibb Company
8.10.1 Company Profile
8.10.2 Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
8.10.3 Bristol-Myers Squibb Company: Financial Performance
8.10.3.1 Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019 (in USD billion)
8.10.3.2 Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018 (in USD billion)
8.10.3.3 Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018 (in USD billion)
8.10.4 Bristol-Myers Squibb Company: Business Strategy
8.10.4.1 Product Level Strategy
8.10.5 SWOT Analysis of Bristol-Myers Squibb Company
Strengths
Weaknesses
Opportunities
Threats
9. COMPETITIVE LANDSCAPE IN U.S. PHARMACEUTICALS MARKET
9.1 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue
9.2 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Global Pharmaceuticals Revenue
9.3 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by United States Pharmaceuticals Revenue
9.4 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Development (R&D) Expenditure
9.5 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earning Per Share (EPS)
9.6 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA)
9.7 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue Forecast
9.8 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Top 3 Product Revenues
10. ANALYSIS OF U.S. PHARMACEUTICALS MARKET
10.1 Porter’s Five Forces Analysis of U.S. Pharmaceuticals Market
10.2 SWOT Analysis of U.S. Pharmaceuticals Market
Strengths
Weaknesses
Opportunities
Threats
11. CURRENT AND FUTURE TRENDS IN U.S. PHARMACEUTICALS MARKET
Orphan Drugs
Biologics and Biosimilars
CURRENT TRENDS
1. Increasing Severity of Drug Price Controls
2. Greater Focus on Rare Diseases / Orphan Drugs
3. Increasing Development of Nucleic Acids as Therapeutics
4. Increasing Focus on Cell Therapy
5. Implantables (Bioelectronics) and Electroceuticals are Expected to Become Mainstream
6. Use of 3D Printing to Reduce Cost and Improve Production Efficiency of Biologics
7. Increasing Use of Big Data and Artificial Intelligence (AI) in Drug Discovery
NOTES
COMPANY INFORMATION
Pfizer Inc.
Johnson & Johnson
Roche Holding AG
AbbVie Inc.
Amgen
Novartis AG
Merck & Co., Inc.
Gilead Sciences, Inc.
Sanofi S.A
Bristol-Myers Squib
LIST OF EXHIBITS
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 U.S. Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
Exhibit 4.1 Forecast for North America Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.2 Country-wise Market Share in North America Pharmaceuticals Market in 2017 (in %)
Exhibit 4.3 Population Forecast for U.S. 2016-2023 (in millions)
Exhibit 4.4 U.S. Pharmaceuticals Market Analysis
Exhibit 4.5 Forecast for U.S. Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 5.1 Growth Drivers and Inhibitors for U.S. Pharmaceuticals Market
Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 7.1 Key Information of FDA
Exhibit 7.2 Contact details of FDA
Exhibit 7.3 Key Information of AAPS
Exhibit 7.4 Contact details of AAPS
Exhibit 7.5 Key Information of PhRMA
Exhibit 7.6 Contact details of PhRMA
Exhibit 7.7 List of PhRMA Members
Exhibit 7.8 Key information of AAM
Exhibit 7.9 Contact details of AAM
Exhibit 7.10 List of AAM Members
Exhibit 8.1 Key Information of Pfizer Inc.
Exhibit 8.2 Contact information of Pfizer Inc.
Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
Exhibit 8.9 SWOT Analysis of Pfizer Inc.
Exhibit 8.10 Key Information of Johnson & Johnson
Exhibit 8.11 Contact information of Johnson & Johnson
Exhibit 8.12 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.13 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 8.14 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.15 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.16 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.16 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.17 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.18 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.19 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.20 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 8.21 SWOT Analysis of Johnson & Johnson
Exhibit 8.22 Key Information of Roche Holding AG
Exhibit 8.23 Contact Information of Roche Holding AG
Exhibit 8.24 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 8.25 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 8.26 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 8.27 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.28 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.29 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.30 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.31 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.32 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.33 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.34 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.35 Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.36 SWOT Analysis of Roche Holding AG
Exhibit 8.37 Roche Holding AG Pharmaceuticals Product Pipeline
Exhibit 8.38 Key information of AbbVie Inc.
Exhibit 8.39 Contact Information of AbbVie. Inc.
Exhibit 8.40 AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.41 Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.42 Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
Exhibit 8.43 Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.44 Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.45 Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
Exhibit 8.46 SWOT Analysis of AbbVie Inc.
Exhibit 8.47 Key information of Amgen Inc.
Exhibit 8.48 Contact details of Amgen Inc.
Exhibit 8.49 Amgen Inc. in Global Pharmaceuticals Manufacturing value chain
Exhibit 8.50 Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)
Exhibit 8.51 Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)
Exhibit 8.52 Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.53 United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.54 United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.55 Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.56 Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.57 Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.58 Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.59 Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.60 Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.61 United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.62 Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.63 Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)
Exhibit 8.64 SWOT Analysis of Amgen Inc
Exhibit 8.65 Key Information of Novartis AG
Exhibit 8.66 Contact Information of Novartis AG
Exhibit 8.67 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.68 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 8.69 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 8.70 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 8.71 Therapy and Geography Area-Wise Revenue of Novartis AG FY 2018 (in USD million)
Exhibit 8.72 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 8.73 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.74 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.75 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.76 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 8.77 SWOT Analysis of Novartis AG
Exhibit 8.78 Key Information of Merck & Co.
Exhibit 8.79 Contact Information of Merck & Co.
Exhibit 8.80 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.81 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.82 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 8.83 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.84 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.85 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.86 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.87 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.88 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 8.89 SWOT Analysis of Merck & Co., Inc.
Exhibit 8.90 Key Information of Gilead Sciences, Inc.
Exhibit 8.91 Contact Information of Gilead Sciences, Inc.
Exhibit 8.92 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.93 Gilead Sciences, Inc. Revenue 2014-2019 (in USD billion)
Exhibit 8.94 Year-wise Gilead Sciences, Inc. Revenue Growth 2014-19 (in %)
Exhibit 8.95 Gilead Sciences, Inc. Geography Wise Revenue Share in (%) 2018
Exhibit 8.96 Gilead Sciences, Inc. Geography Wise Revenue in USD Billion (2016 - 2018)
Exhibit 8.97 Gilead Sciences, Inc. Business Segment Revenue Share 2018
Exhibit 8.98 Gilead Sciences, Inc. Segment wise Revenue in USD Billion (2016- 2018)
Exhibit 8.99 Gilead Sciences, Inc. Revenue from HIV Product Sales (2016-2018)
Exhibit 8.100 Gilead Sciences, Inc. HIV Product Sales by Medicine in USD Million (2018)
Exhibit 8.101 Gilead Sciences, Inc. Revenue from HCV Product Sales (2016-2018)
Exhibit 8.102 Gilead Sciences, Inc. HCV Product Sales by Medicine in USD Million (2018)
Exhibit 8.103 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales (2016-2018)
Exhibit 8.104 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales by Medicine in USD Million (2018)
Exhibit 8.105 Gilead Sciences, Inc. Revenue from Yescarta® Sales (2017-2018)
Exhibit 8.106 SWOT Analysis of Gilead Sciences, Inc.
Exhibit 8.107 Key Information of Sanofi S.A.
Exhibit 8.108 Contact Information of Sanofi S.A.
Exhibit 8.109 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.110 Sanofi S.A. Revenue FY2014-2019 (in Euro billion)
Exhibit 8.111 Year-wise Sanofi S.A. Growth 2014-19 (in %)
Exhibit 8.112 Geography-wise Sanofi S.A. Revenue Share FY 2018 (in %)
Exhibit 8.113 Geography-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.114 Global Business Units (GBU’s)-wise Sanofi S.A. Revenue FY 2018 (in %)
Exhibit 8.115 Global Business Units (GBU’s)-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.116 Global Franchise-wise Sanofi S.A. Revenue FY 2018 (in %)
Exhibit 8.117 Global Franchise-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.118 Sanofi S.A. Speciality Care Franchise Revenue FY 2018 (in %)
Exhibit 8.119 Sanofi S.A. Speciality Care Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.120 Sanofi S.A. Diabetes and Cardiovascular (DCV) Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.121 Sanofi S.A. Established Rx Products Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.122 Sanofi S.A. Consumer Healthcare (CHC) Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.123 Sanofi S.A. Generic Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.124 Sanofi S.A. Vaccines Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.125 SWOT Analysis of Sanofi S.A.
Exhibit 8.126 Top 10 Blockbuster Drug Revenue of Sanofi (in Euro millions)
Exhibit 8.127 Key Information of Bristol-Myers Squib Company
Exhibit 8.128 Contact Information of Bristol-Myers Squib Company
Exhibit 8.129 Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.130 Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.131 Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
Exhibit 8.132 Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
Exhibit 8.133 United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.134 United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.135 Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.136 Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.137 Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.138 Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.139 Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.140 Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.141 Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
Exhibit 8.142 SWOT Analysis of Bristol-Myers Squib Company
Exhibit 9.1 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by United States Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.6 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.7 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by 3 Blockbuster Product Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter’s Five Forces Analysis for U.S. Pharmaceuticals Market
Exhibit 10.2 SWOT Analysis for U.S. Pharmaceuticals Market
Exhibit 2.1 Research and Development Phases of Pharmaceuticals Industry
Exhibit 2.2 Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
Exhibit 2.3 Phase-Wise Research and Development Investment in Pharmaceuticals Industry
Exhibit 2.4 U.S. Pharmaceuticals Industry Value Chain Analysis
Exhibit 3.1 Country-Wise Population Forecast 2016-2023 (in millions)
Exhibit 3.2 Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
Exhibit 4.1 Forecast for North America Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 4.2 Country-wise Market Share in North America Pharmaceuticals Market in 2017 (in %)
Exhibit 4.3 Population Forecast for U.S. 2016-2023 (in millions)
Exhibit 4.4 U.S. Pharmaceuticals Market Analysis
Exhibit 4.5 Forecast for U.S. Pharmaceuticals Market 2018-2023 (in USD billion)
Exhibit 5.1 Growth Drivers and Inhibitors for U.S. Pharmaceuticals Market
Exhibit 6.1 Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
Exhibit 7.1 Key Information of FDA
Exhibit 7.2 Contact details of FDA
Exhibit 7.3 Key Information of AAPS
Exhibit 7.4 Contact details of AAPS
Exhibit 7.5 Key Information of PhRMA
Exhibit 7.6 Contact details of PhRMA
Exhibit 7.7 List of PhRMA Members
Exhibit 7.8 Key information of AAM
Exhibit 7.9 Contact details of AAM
Exhibit 7.10 List of AAM Members
Exhibit 8.1 Key Information of Pfizer Inc.
Exhibit 8.2 Contact information of Pfizer Inc.
Exhibit 8.3 Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.4 Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.5 Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
Exhibit 8.6 Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.7 Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
Exhibit 8.8 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
Exhibit 8.9 SWOT Analysis of Pfizer Inc.
Exhibit 8.10 Key Information of Johnson & Johnson
Exhibit 8.11 Contact information of Johnson & Johnson
Exhibit 8.12 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.13 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 8.14 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 8.15 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.16 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.16 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.17 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 8.18 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.19 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 8.20 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 8.21 SWOT Analysis of Johnson & Johnson
Exhibit 8.22 Key Information of Roche Holding AG
Exhibit 8.23 Contact Information of Roche Holding AG
Exhibit 8.24 Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
Exhibit 8.25 Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
Exhibit 8.26 Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
Exhibit 8.27 Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.28 Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.29 Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.30 County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.31 Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
Exhibit 8.32 County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.33 Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
Exhibit 8.34 Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.35 Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
Exhibit 8.36 SWOT Analysis of Roche Holding AG
Exhibit 8.37 Roche Holding AG Pharmaceuticals Product Pipeline
Exhibit 8.38 Key information of AbbVie Inc.
Exhibit 8.39 Contact Information of AbbVie. Inc.
Exhibit 8.40 AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.41 Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.42 Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
Exhibit 8.43 Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.44 Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
Exhibit 8.45 Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
Exhibit 8.46 SWOT Analysis of AbbVie Inc.
Exhibit 8.47 Key information of Amgen Inc.
Exhibit 8.48 Contact details of Amgen Inc.
Exhibit 8.49 Amgen Inc. in Global Pharmaceuticals Manufacturing value chain
Exhibit 8.50 Revenue of Amgen Inc. FY 2013-FY 2019 (in USD billion)
Exhibit 8.51 Revenue Growth of Amgen Inc FY 2014-FY 2019 (in %)
Exhibit 8.52 Geography-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.53 United States Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.54 United States Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.55 Rest of World Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.56 Rest of World Revenue Growth of Amgen Inc FY 2014-FY 2018 (in %)
Exhibit 8.57 Division-Wise Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.58 Pharmaceuticals Division Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.59 Other Revenue of Amgen Inc FY 2013- FY 2018 (in USD billion)
Exhibit 8.60 Geography-Wise Pharmaceuticals Revenue of Amgen Inc in FY 2018 (in USD billion)
Exhibit 8.61 United States Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.62 Rest of World Pharmaceuticals Revenue of Amgen Inc FY 2013-FY 2018 (in USD billion)
Exhibit 8.63 Brand-Wise Pharmaceuticals Revenue of Amgen Inc FY 2018 (in USD billion)
Exhibit 8.64 SWOT Analysis of Amgen Inc
Exhibit 8.65 Key Information of Novartis AG
Exhibit 8.66 Contact Information of Novartis AG
Exhibit 8.67 Novartis AG in Pharmaceuticals Manufacturing Value Chain
Exhibit 8.68 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
Exhibit 8.69 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
Exhibit 8.70 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
Exhibit 8.71 Therapy and Geography Area-Wise Revenue of Novartis AG FY 2018 (in USD million)
Exhibit 8.72 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
Exhibit 8.73 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.74 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.75 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
Exhibit 8.76 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
Exhibit 8.77 SWOT Analysis of Novartis AG
Exhibit 8.78 Key Information of Merck & Co.
Exhibit 8.79 Contact Information of Merck & Co.
Exhibit 8.80 Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.81 Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
Exhibit 8.82 Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
Exhibit 8.83 Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.84 Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.85 Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
Exhibit 8.86 Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.87 Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
Exhibit 8.88 Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
Exhibit 8.89 SWOT Analysis of Merck & Co., Inc.
Exhibit 8.90 Key Information of Gilead Sciences, Inc.
Exhibit 8.91 Contact Information of Gilead Sciences, Inc.
Exhibit 8.92 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.93 Gilead Sciences, Inc. Revenue 2014-2019 (in USD billion)
Exhibit 8.94 Year-wise Gilead Sciences, Inc. Revenue Growth 2014-19 (in %)
Exhibit 8.95 Gilead Sciences, Inc. Geography Wise Revenue Share in (%) 2018
Exhibit 8.96 Gilead Sciences, Inc. Geography Wise Revenue in USD Billion (2016 - 2018)
Exhibit 8.97 Gilead Sciences, Inc. Business Segment Revenue Share 2018
Exhibit 8.98 Gilead Sciences, Inc. Segment wise Revenue in USD Billion (2016- 2018)
Exhibit 8.99 Gilead Sciences, Inc. Revenue from HIV Product Sales (2016-2018)
Exhibit 8.100 Gilead Sciences, Inc. HIV Product Sales by Medicine in USD Million (2018)
Exhibit 8.101 Gilead Sciences, Inc. Revenue from HCV Product Sales (2016-2018)
Exhibit 8.102 Gilead Sciences, Inc. HCV Product Sales by Medicine in USD Million (2018)
Exhibit 8.103 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales (2016-2018)
Exhibit 8.104 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales by Medicine in USD Million (2018)
Exhibit 8.105 Gilead Sciences, Inc. Revenue from Yescarta® Sales (2017-2018)
Exhibit 8.106 SWOT Analysis of Gilead Sciences, Inc.
Exhibit 8.107 Key Information of Sanofi S.A.
Exhibit 8.108 Contact Information of Sanofi S.A.
Exhibit 8.109 Sanofi S.A. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.110 Sanofi S.A. Revenue FY2014-2019 (in Euro billion)
Exhibit 8.111 Year-wise Sanofi S.A. Growth 2014-19 (in %)
Exhibit 8.112 Geography-wise Sanofi S.A. Revenue Share FY 2018 (in %)
Exhibit 8.113 Geography-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.114 Global Business Units (GBU’s)-wise Sanofi S.A. Revenue FY 2018 (in %)
Exhibit 8.115 Global Business Units (GBU’s)-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.116 Global Franchise-wise Sanofi S.A. Revenue FY 2018 (in %)
Exhibit 8.117 Global Franchise-wise Sanofi S.A. Revenue FY 2017-2018 (in Euro million)
Exhibit 8.118 Sanofi S.A. Speciality Care Franchise Revenue FY 2018 (in %)
Exhibit 8.119 Sanofi S.A. Speciality Care Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.120 Sanofi S.A. Diabetes and Cardiovascular (DCV) Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.121 Sanofi S.A. Established Rx Products Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.122 Sanofi S.A. Consumer Healthcare (CHC) Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.123 Sanofi S.A. Generic Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.124 Sanofi S.A. Vaccines Franchise Revenue FY 2015-2018 (in Euro million)
Exhibit 8.125 SWOT Analysis of Sanofi S.A.
Exhibit 8.126 Top 10 Blockbuster Drug Revenue of Sanofi (in Euro millions)
Exhibit 8.127 Key Information of Bristol-Myers Squib Company
Exhibit 8.128 Contact Information of Bristol-Myers Squib Company
Exhibit 8.129 Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 8.130 Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
Exhibit 8.131 Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
Exhibit 8.132 Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
Exhibit 8.133 United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.134 United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.135 Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.136 Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.137 Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.138 Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.139 Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
Exhibit 8.140 Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
Exhibit 8.141 Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
Exhibit 8.142 SWOT Analysis of Bristol-Myers Squib Company
Exhibit 9.1 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue for FY2018 (in USD billion)
Exhibit 9.2 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.3 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by United States Pharmaceuticals Revenue for FY2018 (in USD billion)
Exhibit 9.4 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
Exhibit 9.5 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
Exhibit 9.6 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
Exhibit 9.7 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by Overall Revenue Forecast for FY2019 (in USD billion)
Exhibit 9.8 Competitive Landscape Among Top 10 U.S. Pharmaceuticals Companies by 3 Blockbuster Product Revenue for FY2018 (in USD billion)
Exhibit 10.1 Porter’s Five Forces Analysis for U.S. Pharmaceuticals Market
Exhibit 10.2 SWOT Analysis for U.S. Pharmaceuticals Market
